ArticleScience translational medicine2020
Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 59 citations in OpenAlex.
- Suppression of astrocyte BMP signaling improves molecular signatures and functional deficits in a fragile X syndrome mouse model.Nature communications · 2026Article
- Cell-intrinsic mechanisms underlying spontaneous activity in the mouse visual cortical slice: implications for fragile X pathophysiology.Journal of neurophysiology · 2026Article
- UBE3A stabilization of β-catenin preserves synaptic proteins essential for motor and cognitive functions in Angelman Syndrome.Molecular autism · 2025Article
- Article
- GSK3α negatively regulates GSK3β by decreasing its protein levels and enzymatic activity in mouse embryonic stem cells.Stem cell reports · 2025Article
- From Discovery to Innovative Translational Approaches in 80 Years of Fragile X Syndrome Research.Biomedicines · 2025Review
- Non-ionotropic signaling through the NMDA receptor GluN2B carboxy-terminal domain drives dendritic spine plasticity and reverses fragile X phenotypes.Cell reports · 2025Article
- GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders.Circulation research · 2025Article
- Inhibition of GSK3α,β rescues cognitive phenotypes in a preclinical mouse model of CTNNB1 syndrome.EMBO molecular medicine · 2024Article
- Review
- SRC family kinase inhibition rescues molecular and behavioral phenotypes, but not protein interaction network dynamics, in a mouse model of Fragile X syndrome.Molecular psychiatry · 2024Article
- mGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS.EMBO molecular medicine · 2024Article
- FMRP phosphorylation modulates neuronal translation through YTHDF1.Molecular cell · 2023Article
- Review
- GSK-3 at the heart of cardiometabolic diseases: Isoform-specific targeting is critical to therapeutic benefit.Biochimica et biophysica acta. Molecular basis of disease · 2023Review
- Do tau-synaptic long-term depression interactions in the hippocampus play a pivotal role in the progression of Alzheimer's disease?Neural regeneration research · 2023Review
- Elucidation of the GSK3α Structure Informs the Design of Novel, Paralog-Selective Inhibitors.ACS chemical neuroscience · 2023Article
- Interactomes of Glycogen Synthase Kinase-3 Isoforms.Journal of proteome research · 2023Article
- GSK3α phosphorylates dynamin-2 to promote GLUT4 endocytosis in muscle cells.The Journal of cell biology · 2023Article
- Mouse models of fragile X-related disorders.Disease models & mechanisms · 2023Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 3 institutions in 1 country.
Patrick K McCamphillPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-7935-4551
Laura J StoppelPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-6673-4988
Rebecca K SenterPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-5650-1187
Michael C LewisStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Arnold J HeynenPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-4313-7405
David C StoppelPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-5900-9240
Vinay SridharUniversity of Texas Southwestern Medical Center, Department of Neuroscience, Dallas, TX 75390, USA.ORCID 0000-0001-5585-1839
Katie A CollinsStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-8787-4135
Xi ShiStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-7691-2239
Jen Q PanStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jon MadisonStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0003-2728-7497
Jeffrey R CottrellStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Kimberly M HuberUniversity of Texas Southwestern Medical Center, Department of Neuroscience, Dallas, TX 75390, USA.ORCID 0000-0002-7479-0661
Edward M ScolnickStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Edward B HolsonStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-9084-237X
Florence F WagnerStanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. mbear@mit.edu fwagner@broadinstitute.org.ORCID 0000-0001-8981-0330
Mark F BearPicower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. mbear@mit.edu fwagner@broadinstitute.org.ORCID 0000-0002-9903-2541
Broad Institute · USMassachusetts Institute of Technology · USThe University of Texas Southwestern Medical Center · US
Funding
Neurophysiological and acute pharmacological studies in FXS patientsU54HD082008 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI HUBER, KIMBERLY M. · 2014 to 2019
$9.8MSynaptic pathophysiology of the 16p11.2 microdeletion mouse modelR01MH106469 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BEAR, MARK F · 2015 to 2019
$2.7MTraining Program in the Neurobiology of Learning and MemoryT32MH074249 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BEAR, MARK F · 2007 to 2016
$1.7MDiscovery of potent, and selective allosteric inhibitors of GSK-3bR03MH087442 · NIMH · BROAD INSTITUTE, INC. · PI HAGGARTY, STEPHEN J, PAN, JEN QIAN · 2009 to 2009
$24kNICHD NIH HHS U54 HD082008NIMH NIH HHS R01 MH106469NIMH NIH HHS T32 MH074249
Abstract
Fragile X syndrome is caused by
Indexed as
Fragile X SyndromeAnimalsDisease Models, AnimalFragile X Messenger Ribonucleoprotein 1Glycogen Synthase Kinase 3HippocampusMiceMice, Inbred C57BLMice, KnockoutFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1Glycogen Synthase Kinase 3
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.